(10 days)
No
The document describes a standard intravascular administration set and its components, with no mention of AI or ML capabilities.
No
The device is used for administering fluids, drugs, and blood into a patient's vascular system, which is a supportive function and not a direct therapeutic treatment of a disease or condition.
No
Explanation: The device is an administration set used to deliver fluids to a patient's vascular system. Its purpose is to administer, not to diagnose.
No
The device description clearly outlines a physical medical device (intravascular administration set with needleless connector) and the performance studies focus on physical characteristics and testing (microbial ingress, shelf life, biocompatibility, etc.), not software validation.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to "administer fluids from a container to a patient's vascular system." This is a direct therapeutic or supportive action on the patient's body, not a test performed on a sample taken from the body to diagnose a condition.
- Device Description: The description reinforces the administration of fluids and highlights features related to that function (needleless connector, sterile, single patient use).
- Lack of IVD Indicators: There is no mention of analyzing samples, detecting substances, or providing diagnostic information.
IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. This device's function is entirely focused on delivering substances into the body.
N/A
Intended Use / Indications for Use
The MaxZero Intravascular Administration set with needleless connector(s) is a device used to administer fluids from a container to a patient's vascular system. The administration set is for single patient use only. The administration set can be used for direct injection, intermittent infusion or continuous infusion.
Product codes
FPA
Device Description
The CareFusion MaxZero Administration Sets are intravascular administration sets intended for single patient use, including pediatrics and immunocompromised patients, for direct injection, intermittent infusion continuous infusion of drugs, blood and fluids. All MaxZero Administration Sets include the previously cleared zero reflux MZ1000 Needleless Connector (K132413) bonded to the extension set tubing. The MZ1000 needleless connector allows thorough and easy disinfection due to a solid, flat smooth surface and eliminates the risk of needlestick injuries. The MaxZero Administration Sets are sterile single patient devices. All extension sets included in this submission are not made from material containing natural rubber latex or DEHP.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Patient's vascular system
Indicated Patient Age Range
pediatrics
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
CareFusion performed design verification performance testing to verify, demonstrate and support the claim of substantial equivalence to the predicate devices. All test results met their acceptance criteria and support that the MaxZero Administration Sets are appropriately designed for their intended use.
Testing performed included:
- Microbial ingress and barrier testing
- Design verification testing
- Shelf life performance testing
- Harsh Infusates testing
- Priming volume/flow rate testing
- Biocompatibility
- Sterilization
The results of the non-clinical testing exhibited that no new issues of safety and efficacy are raised with the proposed introduction of the MaxZero Administration Sets. The device met the acceptance criteria for all functional, microbial ingress, sterility, biocompatibility and other performance criteria, which verify it to be substantially equivalent to the predicate devices. The conclusion drawn from the performance testing demonstrate that the CareFusion MaxZero Administration Sets are as safe as effective and performs at least as safe and effectively as the legally marketed predicate devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 880.5440 Intravascular administration set.
(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.
0
Image /page/0/Picture/11 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
November 20,2014
CareFusion c/o Mark Job Regulatory Technology Services LLC 1394 25th Street N.W. Buffalo, Minnesota 55313
Re: K143234
Trade/Device Name: MaxZero Administration Set Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular administration set Regulatory Class: II Product Code: FPA Dated: November 7, 2014 Received: November 10, 2014
Dear Mark Job:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Susan Runno DDS, MA
Erin I. Keith, M.S Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K143234
Device Name MaxZero Administration Sets
Indications for Use (Describe)
The MaxZero Intravascular Administration set with needleless connector(s) is a device used to administer fluids from a container to a patient's vascular system. The administration set is for single patient use only. The administration set can be used for direct injection, intermittent infusion or continuous infusion.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
] Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
3
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(k) Summary
Submitter Information
| A. Company Name: | CareFusion |
|---|---|
| B. Company Address: | 10020 Pacific Mesa Blvd. |
| San Diego, CA 92121 | |
| C. Company Phone: | (858) 617-3042 |
| D. Company Fax: | (858) 617-5982 |
| E. Contact Person: | Larry Walker |
| F. Date Summary Prepared: | October 14, 2014 |
Device Identification
| A. Trade Name | MaxZero Administration Sets |
|---|---|
| B. Common Name: | IV Administration Sets |
| C. Classification: | IV Administration Set, Needleless Connector, |
| Closed Access, 21 CFR 880.5440, (Product code FPA) |
Legally Marketed Predicate Device for Substantial Equivalence
| Predicate Device | Manufacturer | 510(k) # | Date Cleared |
|---|---|---|---|
| (Primary) Medegen | |||
| Intravascular Administration | |||
| Set and Extension Set | CareFusion (formerly | ||
| Medegen) | K051499 | June 22, 2005 | |
| MZ1000 Needleless Connector | CareFusion | K132413 | August 29, 2013 |
Rational for Substantial Equivalence
The information provided in the premarket notification demonstrates that the subject CareFusion MaxZero Administration Sets are substantially equivalent to the legally marketed predicated devices. The subject MaxZero Administration Sets and the primary predicate Medeqen Administration Sets are intended to be used for the delivery of fluids to an IV catheter in a hospital environment. The subject and the predicate devices are similar in physical properties, materials, and configuration. Each device includes connectors that allow for needleless access to the IV line during IV therapy eliminating the risk of needle injury. The subject device incorporates the predicate MZ1000 Needleless Connector bonded directly to IV tubing. Components of the subject devices are made of materials that are substantial equivalent to the predicate devices listed above and this submission includes comprehensive biocompatibility testing for all device materials included in this submission.
Device Description
The CareFusion MaxZero Administration Sets are intravascular administration sets intended for single patient use, including pediatrics and immunocompromised patients, for direct
1 of 3 Section 5- 510(K) Summary
5
injection, intermittent infusion continuous infusion of drugs, blood and fluids. All MaxZero Administration Sets include the previously cleared zero reflux MZ1000 Needleless Connector (K132413) bonded to the extension set tubing. The MZ1000 needleless connector allows thorough and easy disinfection due to a solid, flat smooth surface and eliminates the risk of needlestick injuries. The MaxZero Administration Sets are sterile single patient devices. All extension sets included in this submission are not made from material containing natural rubber latex or DEHP.
The following model numbers are subject to this submission:
| Model
Number | Description | Tubing
ID | Tubing
OD |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|
| MZXT4001 | MaxZero administration set, microbore tubing, amber tubing, IV
connector, 20 drop drip chamber, filter, check valve, T-connector, ≈95
inch I | 0.020" | 0.079" |
| MZ8001 | MaxZero Administration set, microbore tubing, 3 MaxZero connectors, 20
drop drip chamber, 0.2 micron filter, check valve, anti-siphon valve, 3
colored pinch clamps, spin male luer. ≈ 95 inches | 0.020" | 0.079" |
Intended Use
The MaxZero intravascular administration set with needleless connector(s) is a device used to administer fluids from a container to a patient's vascular system. The administration set is for single patient use only. The administration set can be used for direct injection, intermittent infusion or continuous infusion.
Substantial Equivalence Table
| Device | CareFusion MaxZero Administration Sets | CareFusion (formerly Medegen) Intravascular Administration Set and Extension Set |
|---|---|---|
| 510(k) # | TBD Subject device | K051499 |
| Fluid contacting materials | Needleless Connector: | |
| Polycarbonate, silicone rubber | ||
| Drip Chamber: PVC, ABS | ||
| Polyethylene, Gelman Vespar | ||
| Tubing: PVC | ||
| Bi-F Connector: Rigid PVC | ||
| Back Check Valve: MABS, silicon rubber | ||
| Male Luer Adapter: ABS | ||
| Male Spinloc: ABS | ||
| Female Luer: Copolyester | ||
| Filter: Acrylic, Gulman Supor | Needleless Connector: | |
| Polycarbonate. Liquid silicone rubber | ||
| Drip Chamber: ABS, Polyethylene, PTFE | ||
| Tubing: PVC | ||
| Rotating luer lock: ABS | ||
| Female luer lock: Copolyester | ||
| Male luer lock: Acrylic | ||
| Bi-F Connector: ABS | ||
| Check Valve: ABS, silicone rubber | ||
| Stopcock: Polycarbonate | ||
| Flow Controller: ABS, silicon rubber | ||
| Manifold: ABS, LDPE, silicon rubber, Copolyester | ||
| Filter: Acrylic, Gore-Tex | ||
| Needleless Connector | CareFusion MZ1000 | |
| (K132413) | CareFusion NAC Plus Needleless Connector | |
| (K011193) | ||
| Functional Use | Direct Injection, intermittent infusion, continuous infusion | Direct Injection, intermittent infusion, continuous infusion, aspiration |
| Packaging | Tyvek/polymer pouch | Tyvek/ polymer pouch |
| Sterilization Method | E-Beam | Irradiation |
| Usable Life | Per facility protocol or in accordance with current recognized guidelines for IV therapy. | Per CDC guidelines |
6
Technical Characteristics
| Technological Characteristics |
|---|
| Zero Reflux Needleless Connector |
| Designed to prevent microbial ingress |
| Needleless connector can be disinfected with 3 sec scrub with 70% IPA |
| Non-hemolytic |
| Not made with DEHP |
| Safe for use in MRI environment |
| Not made with natural latex rubber |
| Sets can be used with harsh infusates |
Clinical Data
There is no clinical data included in this submission.
Non-Clinical Data
CareFusion performed design verification performance testing to verify, demonstrate and support the claim of substantial equivalence to the predicate devices. All test results met their acceptance criteria and support that the MaxZero Administration Sets are appropriately designed for their intended use.
Testing performed included:
- Microbial ingress and barrier testing ●
- . Design verification testing
- Shelf life performance testing .
- Harsh Infusates testing
- . Priming volume/flow rate testing
- . Biocompatibility
- Sterilization
For complete list of non-clinical testing please see the following sections.
- . Sterilization: Section 14
- Biocompatibility: Section 15
- Performance Bench: Section 18
Conclusion
The results of the non-clinical testing exhibited that no new issues of safety and efficacy are raised with the proposed introduction of the MaxZero Administration Sets. The device met the acceptance criteria for all functional, microbial ingress, sterility, biocompatibility and other performance criteria, which verify it to be substantially equivalent to the predicate devices. The conclusion drawn from the performance testing demonstrate that the CareFusion MaxZero Administration Sets are as safe as effective and performs at least as safe and effectively as the legally marketed predicate devices.